November 28, 2014 4:12 PM ET

Biotechnology

Company Overview of United Therapeutics Corporation

Company Overview

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops Orenitram, a prostacyclin analog for treatment of PAH; Ch14.18 MAb, an antibody for the treatment of neuroblastoma; Beraprost 314d, which is under Phase III clinical trials for the treatment of PAH; and PLacental eXpanded cells t...

1040 Spring Street

Silver Spring, MD 20910

United States

Founded in 1996

706 Employees

Phone:

301-608-9292

Fax:

301-608-9291

Key Executives for United Therapeutics Corporation

Founder
Age: 59
Total Annual Compensation: $992.7K
President
Age: 52
Total Annual Compensation: $808.1K
Chief Financial Officer
Age: 59
Total Annual Compensation: $543.8K
Executive Vice President of Strategic Planning
Age: 50
Total Annual Compensation: $702.9K
Compensation as of Fiscal Year 2013.

United Therapeutics Corporation Key Developments

Katherine J. Klein Joins the United Therapeutics Corporation Board of Directors

United Therapeutics Corporation announced the appointment of Professor Katherine J. Klein, Ph.D., of The Wharton School of the University of Pennsylvania to its Board of Directors as an independent director. The appointment is effective as of November 11, 2014. Professor Klein has served as the Vice Dean of the Wharton Social Impact Initiative since July 2012, and as The Wharton School's Edward H. Bowman Professor of Management since 2005.

United Therapeutics Corporation Announces Unaudited Consolidated Earnings Results for Third Quarter and Nine Months Ended September 30, 2014

United Therapeutics Corporation announced unaudited consolidated earnings results for third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenues of $329,950 million, operating loss of $32,236 million, loss before income taxes of $35,833 million, net loss of $25,237 million or $0.53 per diluted share compared to the total revenues of $302,225 million, operating income of $104,649 million, income before income taxes of $101,179 million, net income of $62,685 million or $1.17 per diluted share for the same quarter a year ago. For the nine months period, the company reported total revenues of $942,156 million, operating income of $360,223 million, income before income taxes of $350,416 million, net income of $224,139 million or $4.12 per diluted share compared to the total revenues of $827,967 million, operating income of $320,990 million, income before income taxes of $310,533 million, net income of $204,874 million or $3.9 per diluted share for the same period a year ago.

United Therapeutics Corporation to Report Q3, 2014 Results on Oct 28, 2014

United Therapeutics Corporation announced that they will report Q3, 2014 results at 9:00 AM, Eastern Standard Time on Oct 28, 2014

Similar Private Companies By Industry

Company Name Region
Afferent Pharmaceuticals, Inc. United States
Quantapore Inc. United States
Symphony Dynamo, Inc. United States
Armed, L.L.C. United States
Biofilm Technologies, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Buyback
June 27, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact United Therapeutics Corporation, please visit www.unither.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.